What LivaNova’s latest earnings mean for the stock now

LivaNova (NasdaqGS:LIVN) released second quarter 2026 results that showed higher sales and a shift from last year’s loss to net income, which quickly put the stock back on many investors’ radars.

LivaNova’s strong second quarter has landed on top of a share price that is now US$76.22, with a 1 year to date share price return of 25.69% and a 1 year total shareholder return of 56.06%, suggesting momentum has been building despite a softer 30 day share price return of 7.62% and 7 day share price return of 4.89% after the earnings release.

If you are looking beyond LivaNova for other potential healthcare technology ideas, this could be a useful moment to review 43 healthcare AI stocks.

LivaNova has just delivered a sharp uplift in earnings while the share price has already moved higher. Is it more sensible to buy into that strength now, or wait for a more attractive entry as enthusiasm cools and valuation is clearer?

Most Popular Narrative: 10.1% Undervalued

The most followed narrative currently puts LivaNova’s fair value at $84.80, which sits above the last close of $76.22 and frames the recent earnings strength in a valuation context.

The company's clinical innovations, including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability), position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can drive pricing power and higher net margins.

Want to see what this narrative is really baking in? It leans on steadier revenue growth, rising margins, and a richer earnings multiple. The full breakdown connects each assumption to that $84.80 fair value.

Result: Fair Value of $84.80 (UNDERVALUED)

However, the upbeat LivaNova narrative could be challenged if healthcare cost pressure and reimbursement scrutiny limit pricing power, or if R&D spending fails to translate into commercially successful products.

Next Steps

The mixed mood around LivaNova’s latest results and valuation view will not be settled for you by headlines alone, so act quickly and review the underlying data, including the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond LivaNova?

If you stop with LivaNova, you could miss other stocks that fit your style. Take a few minutes to scan for opportunities that suit your goals.

• Target stronger potential value by reviewing companies that look mispriced on quality and fundamentals through the 51 high quality undervalued stocks.
• Strengthen your income stream by scanning for high yield payers that aim to balance reliability with return using the 8 dividend fortresses.
• Dial down risk by focusing on companies with robust finances and low risk profiles via the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.